Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.70 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18929812 | 0.90 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 | |
| SCHEMBL19651827 | 0.88 | HPGD (0.65) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 | |
| SCHEMBL19651816 | 0.88 | HPGD (0.61) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 | |
| SCHEMBL11976991 | 0.85 | POLB (0.57) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 | |
| SCHEMBL9173237 | 0.85 | KMT2A (0.77) | KMT2AGLAL3MBTL1HPGDALDH1A1 | |
| SCHEMBL13816278 | 0.85 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 | |
| SCHEMBL487641 | 0.82 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 | |
| SCHEMBL12545945 | 0.82 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 | |
| SCHEMBL14345429 | 0.82 | KMT2A (0.73) | KMT2AGLAL3MBTL1HPGDALDH1A1 | |
| SCHEMBL11976994 | 0.81 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1KMT2AGLAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | HSP90AA1 1463/4885HSP90AB1 1429/4885KMT2A 2222/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | HSP90AA1 1463/4885HSP90AB1 1429/4885KMT2A 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.